Not Yet RecruitingPhase 1

Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

United States14 participantsStarted 2026-05-27

Plain-language summary

This clinical trial assesses whether it is feasible to use radiation therapy with vancomycin prior to CAR T-cell therapy for patients with large B-cell lymphomas

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female subject aged ≥ 18 years. * Pathologically confirmed B-cell lymphoma patients intended for standard of care CAR-T * ECOG Performance Status ≤ 2. * Subjects must be clinically eligible to receive standard of care anti-CD19 CAR-T * Subjects must have at least one site of disease amenable to radiation, with the ability to deliver radiation to at least 50% of involved sites * Subjects must have at least one site of measurable disease based on CT or FDG PET * Subjects must not be anticipated to require additional therapy beyond bridging radiation listed in this protocol for control of their lymphoma * For female subjects: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: Women \< 50 years of age: amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or Underwent surgical sterilization (bilateral oophorectomy or hysterectomy). Women ≥ 50 years of age: amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or had radiation-induced menopause with last menses \>1 year ago; or had chemotherapy-induced menopause with last menses \>1 year ago; or underwent surgical sterilization (bilateral ooph…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Cytokine release syndrome

Timeframe: date of CAR-T infusion to 28 days after infusion

Severe adverse events

Timeframe: CAR-T infusion to 28 days after infusion

VRE

Timeframe: start of vancomycin to day 28 after CAR-T infusion

Adverse Events

Timeframe: start of vancomycin until day 28 after CAR-T infusion

Trial details

NCT IDNCT07478848

SponsorAbramson Cancer Center at Penn Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-01-01

Contact for this trial

Rachel Lundberg, PA-C

215-615-5858 rachel.lundberg@pennmedicine.upenn.edu

View on ClinicalTrials.gov More Large B Cell Lymphoma trials